Short Interest in Progyny, Inc. (NASDAQ:PGNY) Increases By 41.0%

Progyny, Inc. (NASDAQ:PGNY) was the recipient of a large growth in short interest in February. As of February 13th, there was short interest totaling 4,015,675 shares, a growth of 41.0% from the January 29th total of 2,847,787 shares. Currently, 5.1% of the company’s shares are short sold. Based on an average daily volume of 1,363,392 shares, the days-to-cover ratio is currently 2.9 days. Based on an average daily volume of 1,363,392 shares, the days-to-cover ratio is currently 2.9 days. Currently, 5.1% of the company’s shares are short sold.

Progyny Price Performance

Progyny stock traded down $0.08 during trading hours on Tuesday, hitting $17.52. The company had a trading volume of 2,021,794 shares, compared to its average volume of 1,550,125. Progyny has a fifty-two week low of $16.75 and a fifty-two week high of $28.75. The firm has a market capitalization of $1.43 billion, a P/E ratio of 26.95, a price-to-earnings-growth ratio of 1.20 and a beta of 1.01. The firm’s fifty day moving average is $23.56 and its 200-day moving average is $23.04.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company had revenue of $318.40 million during the quarter, compared to analyst estimates of $314.26 million. During the same quarter last year, the business posted $0.42 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Analysts anticipate that Progyny will post 0.6 earnings per share for the current year.

Institutional Investors Weigh In On Progyny

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Progyny by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock valued at $217,484,000 after buying an additional 235,513 shares during the last quarter. State Street Corp boosted its holdings in Progyny by 1.5% during the fourth quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after acquiring an additional 44,642 shares during the period. Wellington Management Group LLP boosted its holdings in Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after acquiring an additional 1,621,688 shares during the period. Ameriprise Financial Inc. grew its position in shares of Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after purchasing an additional 545,431 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Progyny by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock worth $50,655,000 after purchasing an additional 20,533 shares during the period. Institutional investors own 94.93% of the company’s stock.

Wall Street Analysts Forecast Growth

PGNY has been the topic of several analyst reports. Citigroup raised shares of Progyny to an “outperform” rating in a research report on Tuesday, January 20th. Zacks Research lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. BTIG Research restated a “buy” rating on shares of Progyny in a report on Wednesday, January 21st. Finally, Canaccord Genuity Group raised their target price on Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a research report on Monday, November 17th. Eight research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $28.80.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.